NCT07440043Not yet recruiting
Relugolix for Endometriosis Associated Pain
An Ambispective, Single-center Observational Study Evaluating the Effectiveness of Relugolix Combination Therapy in Reducing Endometriosis-associated Pain Over 24 Weeks in a Real-world Clinical Setting
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
Endometriosis is a chronic, estrogen-dependent condition frequently associated with pelvic pain and reduced quality of life. Relugolix combination therapy (CT), an oral GnRH receptor antagonist-based treatment, has demonstrated efficacy in randomized clinical trials, but real-world data remain limited. The RELAX study is a single-center, ambispective observational study evaluating the effectiveness of relugolix CT in reducing endometriosis-associated pain over 24 weeks in routine clinical practice. The primary endpoint is the change from baseline in pelvic pain measured by the Visual Analog Scale (VAS). Secondary outcomes include changes in pain-related symptoms, ultrasonographic findings, patient satisfaction, and safety.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 33 (estimated)
- First submitted
- 23 Feb 2026
- Start date
- 25 Feb 2026
- Primary completion date
- 25 Dec 2026
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Endometriosis
- NCT number
- NCT07440043
What you commit to
- Study type: Observational
- Planned participants: 33
- From 25 Feb 2026 to the primary completion date, 25 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Menopausal status (natural or surgical)
Who the study is looking for
- Female aged between 18 and 50 years
- Endometriosis confirmed laparoscopically or radiologically (via ultrasound or MRI)
- Receiving treatment with Relugolix CT according to clinical practice for at least one month
- Pain score ≥40 on the VAS scale
- Regular menstrual cycles, (i.e., not in a menopausal or perimenopausal state)
- Signed informed consent
Age in the registry: 18 years to 50 years · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.